HER-2 codon 655 polymorphism in cervical carcinogenesis

Ueda, Masatsugu; Hung, Yao-Ching; Saito, Junko; Nunobiki, Osamu; Noda, Sadamu; Ueki, Minoru

doi:10.1111/j.1525-1438.2006.00349.x

Cited by 4 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the function of HER2 exonic polymorphism is clear, the association between HER2 SNP rs1136201 and CCa is still controversial 28,29. Our results show that rs1136201 alone does not significantly influence the risk of CCa, which coincide to the previous report in a Japanese population 28; however our results do not align with the population in Poland 29. Such difference might be due to the distinction of Asian and Caucasian populations.…”

Section: Discussioncontrasting

confidence: 66%

“…Variant of rs1136201 might lead to destabilization of the active HER2 heterodimers, consequently increases signal transduction for HER2 expression, and finally stimulates kinase activity and malignant transformation 26, 27. Although the function of HER2 exonic polymorphism is clear, the association between HER2 SNP rs1136201 and CCa is still controversial 28,29. Our results show that rs1136201 alone does not significantly influence the risk of CCa, which coincide to the previous report in a Japanese population 28; however our results do not align with the population in Poland 29.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of HER2 Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population

et al. 2019

View full text Add to dashboard Cite

Background: Cervical cancer (CCa) is a multifactorial gynecologic disease worldwide. Effects of HER2 polymorphisms, especially those in exonic region, have been investigated in many gynecologic diseases. In this study, we evaluated the influence of functional HER2 polymorphisms on susceptibility and survival of CCa in a Chinese population.Methods: We genotyped the HER2 exonic polymorphisms by TaqMan in both case-control study (413 CCa patients vs. 396 controls) and survival study (413 CCa patients). Logistic regression and Cox regression were adopted to evaluate the genetic association with the risk and outcomes of CCa, respectively.Results: In the case-control study, there was no significant difference between patients and controls in either HER2 rs1136201 or rs1058808. However, when combined, these two polymorphisms demonstrated a significant hazardous effect for CCa (P = 0.012). Besides, number of variants was also influential (P trend =0.002). In survival analysis, dominant model of rs1136201 and co-dominant modelof rs1058808 were significantly associated with the survival (P = 0.037 and P =0.028). The combination of rs1136201 and rs1058808 also negatively impacted CCa survival (P = 0.009). Cox regression further revealed the significance of the polymorphism combination (β = 0.38, P = 0.025, HR= 1.47, 95%CI = 1.05-2.05). Functional assay of these polymorphisms demonstrated that rs1058808 G allele was associated with stronger expression of HER2 gene.Conclusions: Our results suggested that the combination of HER2 rs1136201and rs1058808 was significantly associated with the susceptibility of CCa. Besides, this combination of polymorphism s also substantially impacted the survival of CCa patients.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Discussionmentioning

confidence: 99%

The Effect of HER2 Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Both mNeuNT and the human ErbB2 codon 655 polymorphism are single amino acid changes within the transmembrane domain of ErbB2 [47]–[49] suggesting that the transmembrane domain mediates critical interactions in disease. Interestingly, low grade in situ lesions of the cervix are not associated with this polymorphism [50] while advanced cervical cancer is strongly associated with it [51]. In head and neck squamous cell carcinoma, codon 655 polymorphism is associated with malignancy [52].…”

Section: Discussionmentioning

confidence: 99%

ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers

et al. 2012

View full text Add to dashboard Cite

In non-cancerous cells, phosphorylated proteins exist transiently, becoming de-phosphorylated by specific phosphatases that terminate propagation of signaling pathways. In cancers, compromised phosphatase activity and/or expression occur and contribute to tumor phenotype. The non-receptor phosphatase, PTPN13, has recently been dubbed a putative tumor suppressor. It decreased expression in breast cancer correlates with decreased overall survival. Here we show that PTPN13 regulates a new signaling complex in breast cancer consisting of ErbB2, Src, and EphrinB1. To our knowledge, this signaling complex has not been previously described. Co-immunoprecipitation and localization studies demonstrate that EphrinB1, a PTPN13 substrate, interacts with ErbB2. In addition, the oncogenic V660E ErbB2 mutation enhances this interaction, while Src kinase mediates EphrinB1 phosphorylation and subsequent MAP Kinase signaling. Decreased PTPN13 function further enhances signaling. The association of oncogene kinases (ErbB2, Src), a signaling transmembrane ligand (EphrinB1) and a phosphatase tumor suppressor (PTPN13) suggest that EphrinB1 may be a relevant therapeutic target in breast cancers harboring ErbB2-activating mutations and decreased PTPN13 expression.

show abstract

“…34 These data suggest the possibility that the HER2 +655 A/G polymorphism might contribute to the disease susceptibility of these cancers. However, Ueda et al 36 36 Wang et al, 35 and McKay et al 38 Fleishman et al 41 suggested that the HER2 +655 A/G polymorphism was possibly associated with the structural and functional alteration of the HER2 protein since it is located in the transmembrance coding region. 42 Interestingly, the activation of HER2 was thought to be correlated with the hormone refractory state of endometrial cancer.…”

Section: Discussionmentioning

confidence: 96%

“…34 These data suggest the possibility that the HER2 +655 A/G polymorphism might contribute to the disease susceptibility of these cancers. However, Ueda et al 36 demonstrated that this polymorphism was not associated with the onset of uterine cervical cancer in a Japanese population. Wang et al 35 failed to show an association between bladder cancer and this polymorphism in a Japanese population.…”

Section: Discussionmentioning

confidence: 98%

Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Gene Polymorphisms in Endometrial Cancer in a Japanese Population

et al. 2007

View full text Add to dashboard Cite

Endometrial cancer is associated with both EGFR and HER2 receptor activation. The EGFR and HER2 genes could be disease susceptibility candidate genes for this cancer. This study was conducted to investigate a possible association between EGFR and HER2 gene polymorphisms and endometrial cancer and the influence of these polymorphisms on the clinical outcome of endometrial cancer patients in a Japanese population. The authors compare the genotype distributions and allele frequencies of the EGFR +2073 A/T and HER2 +655 A/G polymorphisms in 116 endometrial cancer patients and 213 controls using polymerase chain reaction-restriction fragment length polymorphism (RFLP) analysis. RFLP results were confirmed by direct DNA sequencing. Of the 116 patients, 76 (65.5%) could be followed up. Disease-free survival estimates were computed using the Kaplan-Meier method, and differences between survival periods were assessed using the log-rank test. No significant differences were observed in either genotype distributions or allele frequencies in the EGFR +2073 A/T and HER2 +655 A/G polymorphisms between endometrial cancer patients and controls. The stratification by histological types and staging failed to identify significant differences between endometrial cancer patients and controls. No statistical differences were noted between these polymorphisms and disease-free survival (Kaplan-Meier log-rank test P = .55 and .66, for the EGFR +2073 A/T and HER2 +655 A/G, respectively). These results suggest that the EGFR +2073 A/T and HER2 +655 A/G polymorphisms are not associated with endometrial cancer in a Japanese population. These conclusions are based on relatively small numbers and will require verification from additional independent studies.

show abstract

HER-2 codon 655 polymorphism in cervical carcinogenesis

Cited by 4 publications

References 37 publications

The Effect of HER2 Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population

The Effect of HER2 Single Nucleotide Polymorphisms on Cervical Cancer Susceptibility and Survival in a Chinese Population

ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers

Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Gene Polymorphisms in Endometrial Cancer in a Japanese Population

Contact Info

Product

Resources

About